



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

REC'D 09 JUL 2003

WIPO PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02100588.9

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

R C van Dijk



Anmeldung Nr:  
Application no.: 02100588.9  
Demande no:

Anmeldetag:  
Date of filing: 30.05.02  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

DSM N.V.  
Het Overloon 1  
6411 TE Heerlen  
PAYS-BAS

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se référer à la description.)

NOVEL PECTINASE PEC7 AND USES THEREOF

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)  
revendiquée(s)  
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

C12N9/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of  
filing/Etats contractants désignées lors du dépôt:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

## NOVEL PECTINASE PEC7 AND USES THEREOF

**Field of the invention**

5                   The invention relates to newly identified polynucleotide sequences comprising genes that encode novel pectinases isolated from *Aspergillus niger*. The invention features the full length nucleotide sequence of the novel gene, the cDNA sequence comprising the full length coding sequence of the novel pectinase as well as the amino acid sequence of the full-length  
10 functional protein and functional equivalents thereof. The invention also relates to methods of using these enzymes in industrial processes and methods of diagnosing fungal infections. Also included in the invention are cells transformed with a polynucleotide according to the invention and cells wherein a pectinase according to the invention is genetically modified to enhance or reduce its activity  
15 and/or level of expression.

**Background of the invention**

                  Pectin polymers are important constituents of plant primary cell  
20 walls. They are composed of chains of 1,4-linked alpha-D-galacturonic acid and methylated derivatives thereof. Enzymes that are able to degrade the above-defined pectin polymers are called pectinases. Degradation in this respect means that at least one sugar residue or ester group has been removed from the pectin molecule. Pectinases such as polygalacturonase, pectin methylesterase, pectin  
25 lyase or pectate lyase are important for the food industry, primarily in the art of fruit and vegetable processing such as fruit juice production or wine making, where their ability to catalyse the degradation of the backbone of the pectin polymer is utilised. Another application of pectinases, in particular pectin methyl  
30 esterase, is the firming of fruit and vegetables.

                  The seeds of leguminosae like soy beans and other types of  
35 peas also contain pectin. This pectin, however, is quite different from pectins described for fruits like apple berries etc. A large part of soybean pectin is water-insoluble. In addition soybean pectin consists mainly of xylogalacturonan and rhamnogalacturonan and contains only minor amounts of homogalacturonan. The  
CDTA-soluble pectic substances from soybean meal are composed of

5 rhamnogalacturonan and xylogalacturonan but not homogalacturonan. Due to these structural differences soybean pectin is much more difficult to degrade by pectinases as compared to fruit pectin. Even the use of technical multi-enzyme preparations was not sufficient to degrade soybean pectin structures (Huisman, MMH; Schols, HA; Voragen, AGJ, **1999**, Enzymatic degradation of cell wall polysaccharides from soybean meal, Carbohydrate Polymers 38, 299-307, and: Ouhida, I; Pérez, JF; Gasa, J; **2002**, Soybean (glycine max) cell wall composition and availability to feed enzymes, J. Agric. Food Chem 50, 1933-1938).

10 An assortment of different pectin degrading enzymes is known to be present in various microorganisms such as *Aspergillus niger*.

The following is a non-exhaustive list of pectin-acting enzymes:

Enzyme	E.C. Number
exopolygalacturonase	3.2.1.67
endopolygalacturonase	3.2.1.15
pectin lyase	4.2.2.10
pectate lyase	4.2.2.2
rhamnogalacturonan hydrolase	3.2.1.x
rhamnogalacturonan lyase	4.2.2.x
rhamnogalacturonan acetylesterase	3.1.1.x
RG rhamnohydrolase	3.2.1.x
RG galacturonohydrolase	3.2.1.x
xylogalacturonan hydrolase	3.2.1.x
pectin acetylesterase	3.1.1.x
pectin methylesterase	3.1.1.11
endo-arabinase	3.2.1.99
beta-arabinofuranosidase	3.2.1.55
beta-1,4-galactanase	3.2.1.89
beta-1,3-galactanase	3.2.1.90
beta-galactosidase	3.2.1.23
alpha-galactosidase	3.2.1.22

feruloyl acetyl esterase	3.1.1.x
alpha-fucosidase	3.2.1.51
(beta-fucosidase)	3.2.1.38
beta-apiosidase	3.2.1.x
alpha-rhamnosidase	3.2.1.40
beta-rhamnosidase	3.2.1.43
alpha-arabinopyranosidase	3.2.1.x
beta-glucuronidase	3.2.1.31
(alpha-glucuronidase)	3.2.1.139
beta-xylosidase	3.2.1.37
(alpha-xylosidase)	3.2.1.x

Pectin methylesterase catalyses the removal of methanol from pectin, resulting in the formation of pectic acid (polygalacturonic acid). Pectate lyase cleaves glycosidic bonds in polygalacturonic acid by beta-elimination, pectin lyase cleaves the glycosidic bonds of highly methylated pectins by beta-elimination, and polygalacturonase hydrolyses the glycosidic linkages in the polygalacturonic acid chain.

Commercially available pectinases are actually a mixture of enzymes, which, along with other enzymes such as cellulases, are used in the fruit industry to help extract, clarify and modify fruit juices.

It is a disadvantage of these mixtures that they hardly ever contain the optimal mix of enzymes to treat a particular fruit or juice. Optimal pectin degradation depends on many factors, including the kind of fruit to be treated, the season in which the fruit is harvested, the ripeness of the fruit, and many more. A well-known example is the release of unwanted methanol and methylated pectin by the action of pectinmethylesterases and/or exo-polygalacturonases when present in too high concentrations. It is therefore an object of the present invention to provide isolated (recombinant) pectinases. The availability of isolated enzymes allows a cocktail of enzymes to be prepared which is optimized for the digestion of pectin from a particular fruit or juice.

Pectinases have been cloned in a variety of different microorganisms. Molecular cloning of pectinases in fungi has also been described. The DNA and deduced amino acid sequences of pectinases from *Aspergillus oryzae*, *Aspergillus kawachii* and *Emmericella nidulans* are known.

However, there is still a need for other pectinases with different

properties so that fruit processing may be optimized.

One of the disadvantages of the currently available enzymes is that they have pH optima above pH 4.0. Many fruit juices are more acidic and a pH optimum below 3.8 would be desirable. Fruit juices may become as acidic as pH 2.0 and it is therefore an object of the present invention to provide pectinases with a more acidic pH optimum. Pectinases with a pH optimum below 3.8 would be especially advantageous.

Fruit processing is also often performed at more extreme temperatures. Use of pectinases with lower temperature optima would improve yield and quality of the juice because more aromas would be released. The currently available enzymes have a very low efficiency at temperatures below 15 °C. Also, at high temperatures the currently available enzymes are easily inactivated. This is a disadvantage for those fruit juices that have to be pasteurized.

The enzymes according to the invention provide a better temperature stability and can withstand more extreme temperatures in comparison with pectinases according to the prior art.

Also, the specificity of current enzymes leaves to be desired. Fruit juice that needs to be filtrated after or during processing tends to clot the filters after some time. This is due to the inability of certain enzymes to properly digest fruit polysaccharides which causes the fouling of the filters.

The present invention addresses at least one if not all of the above problems.

### **Object of the invention**

It is an object of the invention to provide novel polynucleotides encoding novel pectinases with improved properties. A further object is to provide naturally and recombinantly produced pectinases as well as recombinant strains producing these. Also fusion polypeptides are part of the invention as well as methods of making and using the polynucleotides and polypeptides according to the invention.

### **Summary of the invention**

The invention provides for novel polynucleotides encoding novel pectinases.

More in particular, the invention provides for polynucleotides having a nucleotide sequence that hybridises preferably under highly stringent

conditions to a sequence according to SEQ ID NO: 1 or SEQ ID NO: 2.

Consequently, the invention provides nucleic acids that are more than 40% such as about 60%, preferably 65%, more preferably 70%, even more preferably 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% homologous to the sequences

5 according to SEQ ID NO: 1 or SEQ ID NO: 2.

In a more preferred embodiment the invention provides for such an isolated polynucleotide obtainable from a filamentous fungus, in particular *A. niger* is preferred.

10 In one embodiment, the invention provides for an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide with an amino acid sequence as shown in SEQ ID NO: 3 or functional equivalents thereof.

In a further preferred embodiment, the invention provides an isolated polynucleotide encoding at least one functional domain of a polypeptide according to SEQ ID NO: 3 or functional equivalents thereof.

15 In a preferred embodiment the invention provides an pectinase gene according to SEQ ID NO: 1. In another aspect the invention provides a polynucleotide, preferably a cDNA encoding an *A. niger* pectinase whose amino acid sequence is shown in SEQ ID NO: 3 or variants or fragments of that polypeptide. In a preferred embodiment the cDNA has a sequence according to SEQ ID NO: 2 or functional equivalents thereof.

20 In an even further preferred embodiment, the invention provides for a polynucleotide comprising the coding sequence of the polynucleotides according to the invention, preferred is the polynucleotide sequence of SEQ ID NO: 2.

25 The invention also relates to vectors comprising a polynucleotide sequence according to the invention and primers, probes and fragments that may be used to amplify or detect the DNA according to the invention.

30 In a further preferred embodiment, a vector is provided wherein the polynucleotide sequence according to the invention is functionally linked with regulatory sequences suitable for expression of the encoded amino acid sequence in a suitable host cell, such as *A. niger* or *A. oryzae*. The invention also provides methods for preparing polynucleotides and vectors according to the invention.

35 The invention also relates to recombinantly produced host cells

that contain heterologous or homologous polynucleotides according to the invention.

In another embodiment, the invention provides recombinant host cells wherein the expression of an pectinase according to the invention is  
5 significantly increased or wherein the activity of the pectinase is increased.

In another embodiment the invention provides for a recombinantly produced host cell that contains heterologous or homologous DNA according to the invention and wherein the cell is capable of producing a functional pectinase according to the invention, preferably a cell capable of over-  
10 expressing the pectinase according to the invention, for example an *Aspergillus* strain comprising an increased copy number of a gene or cDNA according to the invention.

In yet another aspect of the invention, a purified polypeptide is provided. The polypeptides according to the invention include the polypeptides  
15 encoded by the polynucleotides according to the invention. Especially preferred is a polypeptide according to SEQ ID NO: 3 or functional equivalents thereof.

Fusion proteins comprising a polypeptide according to the invention are also within the scope of the invention. The invention also provides methods of making the polypeptides according to the invention.

20 The invention also relates to the use of the pectinase according to the invention in any industrial process as described herein

### **Detailed description of the invention**

#### **25 Polynucleotides**

The present invention provides polynucleotides encoding an pectinase, tentatively called PEC7, having an amino acid sequence according to SEQ ID NO: 3 or functional equivalents thereof. The sequence of the gene encoding PEC7 was determined by sequencing a genomic clone obtained from  
30 *Aspergillus niger*. The invention provides polynucleotide sequences comprising the gene encoding the PEC7 pectinase as well as its complete cDNA sequence and its coding sequence. Accordingly, the invention relates to an isolated polynucleotide comprising the nucleotide sequence according to SEQ ID NO: 1 or SEQ ID NO: 2 or functional equivalents thereof.

35 More in particular, the invention relates to an isolated polynucleotide hybridisable under stringent conditions, preferably under highly stringent conditions, to a polynucleotide according to SEQ ID NO: 1 or SEQ ID



NO: 2. Advantageously, such polynucleotides may be obtained from filamentous fungi, in particular from *Aspergillus niger*. More specifically, the invention relates to an isolated polynucleotide having a nucleotide sequence according to SEQ ID NO: 1 or SEQ ID NO: 2.

5                   The invention also relates to an isolated polynucleotide encoding at least one functional domain of a polypeptide according to SEQ ID NO: 3 or functional equivalents thereof.

                  As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules which may be isolated from chromosomal DNA, which  
10                  include an open reading frame encoding a protein, e.g. an *A. niger* pectinase. A gene may include coding sequences, non-coding sequences, introns and regulatory sequences. Moreover, a gene refers to an isolated nucleic acid molecule as defined herein.

                  A nucleic acid molecule of the present invention, such as a  
15                  nucleic acid molecule having the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 2 or a functional equivalent thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. For example, using all or portion of the nucleic acid sequence of SEQ ID NO: 1 or the nucleotide  
20                  sequence of SEQ ID NO: 2 as a hybridization probe, nucleic acid molecules according to the invention can be isolated using standard hybridization and cloning techniques (e. g., as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

                  Moreover, a nucleic acid molecule encompassing all or a portion  
25                  of SEQ ID NO: 1 or SEQ ID NO: 2 can be isolated by the polymerase chain reaction (PCR) using synthetic oligonucleotide primers designed based upon the sequence information contained in SEQ ID NO:1 or SEQ ID NO: 2.

                  A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate  
30                  oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis.

                  Furthermore, oligonucleotides corresponding to or hybridisable to nucleotide sequences according to the invention can be prepared by standard  
35                  synthetic techniques, e. g., using an automated DNA synthesizer.

                  In a preferred embodiment, an isolated nucleic acid molecule of

the invention comprises the nucleotide sequence shown in SEQ ID NO: 2. The sequence of SEQ ID NO: 2 corresponds to the coding region of the *A. niger* PEC7 cDNA. This cDNA comprises sequences encoding the *A. niger* PEC7 polypeptide according to SEQ ID NO: 3.

5 In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO: 2 or a functional equivalent of these nucleotide sequences.

10 A nucleic acid molecule which is complementary to another nucleotide sequence is one which is sufficiently complementary to the other nucleotide sequence such that it can hybridize to the other nucleotide sequence thereby forming a stable duplex.

15 One aspect of the invention pertains to isolated nucleic acid molecules that encode a polypeptide of the invention or a functional equivalent thereof such as a biologically active fragment or domain, as well as nucleic acid molecules sufficient for use as hybridisation probes to identify nucleic acid molecules encoding a polypeptide of the invention and fragments of such nucleic acid molecules suitable for use as PCR primers for the amplification or mutation of nucleic acid molecules.

20 An "isolated polynucleotide" or "isolated nucleic acid" is a DNA or RNA that is not immediately contiguous with both of the coding sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived. Thus, in one embodiment, an isolated nucleic acid includes some or all of the 5' non-coding  
25 (e.g., promotor) sequences that are immediately contiguous to the coding sequence. The term therefore includes, for example, a recombinant DNA that is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA or a genomic DNA fragment produced by PCR or  
30 restriction endonuclease treatment) independent of other sequences. It also includes a recombinant DNA that is part of a hybrid gene encoding an additional polypeptide that is substantially free of cellular material, viral material, or culture medium (when produced by recombinant DNA techniques), or chemical precursors or other chemicals (when chemically synthesized). Moreover, an  
35 "isolated nucleic acid fragment" is a nucleic acid fragment that is not naturally occurring as a fragment and would not be found in the natural state.

As used herein, the terms "polynucleotide" or "nucleic acid molecule" are intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA. The nucleic acid may be synthesized using oligonucleotide analogs or derivatives (e.g., inosine or phosphorothioate nucleotides). Such oligonucleotides can be used, for example, to prepare nucleic acids that have altered base-pairing abilities or increased resistance to nucleases.

Another embodiment of the invention provides an isolated nucleic acid molecule which is antisense to a PEC7 nucleic acid molecule, e.g., the coding strand of a PEC7 nucleic acid molecule. Also included within the scope of the invention are the complement strands of the nucleic acid molecules described herein.

#### Sequencing errors

The sequence information as provided herein should not be so narrowly construed as to require inclusion of erroneously identified bases. The specific sequences disclosed herein can be readily used to isolate the complete gene from filamentous fungi, in particular *A. niger* which in turn can easily be subjected to further sequence analyses thereby identifying sequencing errors.

Unless otherwise indicated, all nucleotide sequences determined by sequencing a DNA molecule herein were determined using an automated DNA sequencer and all amino acid sequences of polypeptides encoded by DNA molecules determined herein were predicted by translation of a DNA sequence determined as above. Therefore, as is known in the art for any DNA sequence determined by this automated approach, any nucleotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence can be more precisely determined by other approaches including manual DNA sequencing methods well known in the art. As is also known in the art, a single insertion or deletion in a determined nucleotide sequence compared to the actual sequence will cause a frame shift in translation of the nucleotide sequence such that the predicted amino acid sequence encoded by a determined nucleotide sequence will be completely

different from the amino acid sequence actually encoded by the sequenced DNA molecule, beginning at the point of such an insertion or deletion.

The person skilled in the art is capable of identifying such erroneously identified bases and knows how to correct for such errors.

5

### **Nucleic acid fragments, probes and primers**

A nucleic acid molecule according to the invention may comprise only a portion or a fragment of the nucleic acid sequence shown in SEQ ID NO:1 or SEQ ID NO:2, for example a fragment which can be used as a probe or primer or a fragment encoding a portion of a PEC7 protein. The nucleotide sequence determined from the cloning of the PEC7 gene and cDNA allows for the generation of probes and primers designed for use in identifying and/or cloning other PEC7 family members, as well as PEC7 homologues from other species.

15 The probe/primer typically comprises substantially purified oligonucleotide which typically comprises a region of nucleotide sequence that hybridizes preferably under highly stringent conditions to at least about 12 or 15, preferably about 18 or 20, preferably about 22 or 25, more preferably about 30, 35, 40, 45, 50, 55, 60, 65, or 75 or more consecutive nucleotides of a nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO: 2 or of a functional equivalent thereof.

20

Probes based on the PEC7 nucleotide sequences can be used to detect transcripts or genomic PEC7 sequences encoding the same or homologous proteins for instance in other organisms. In preferred embodiments, the probe further comprises a label group attached thereto, e.g., the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme cofactor. Such probes can also be used as part of a diagnostic test kit for identifying cells which express a PEC7 protein.

25

### **Identity & homology**

30

The terms "homology" or "percent identity" are used interchangeably herein. For the purpose of this invention, it is defined here that in order to determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid

35

positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of  
5 the number of identical positions shared by the sequences (i.e., % identity = number of identical positions/total number of positions (i.e. overlapping positions) x 100). Preferably, the two sequences are the same length.

The skilled person will be aware of the fact that several different computer programmes are available to determine the homology between two  
10 sequences. For instance, a comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (J. Mol. Biol. (48):444-453 (1970)) algorithm which has been incorporated into the  
15 GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. The skilled person will appreciate that all these different parameters will yield slightly different results but that the overall percentage identity of two sequences is not significantly altered  
20 when using different algorithms.

In yet another embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at <http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In  
25 another embodiment, the percent identity two amino acid or nucleotide sequence is determined using the algorithm of E. Meyers and W. Miller (CABIOS, 4:11-17 (1989) which has been incorporated into the ALIGN program (version 2.0) (available at: <http://vega.igh.cnrs.fr/bin/align-guess.cgi>) using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

30 The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403—10. BLAST nucleotide  
35 searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to PEC7 nucleic acid molecules of

the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to PEC7 protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>.

### **Hybridisation**

As used herein, the term "hybridizing" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least about 50%, at least about 60%, at least about 70%, more preferably at least about 80%, even more preferably at least about 85% to 90%, more preferably at least 95% homologous to each other typically remain hybridized to each other.

A preferred, non-limiting example of such hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45 °C, followed by one or more washes in 1 X SSC, 0.1 % SDS at 50 °C, preferably at 55 °C, preferably at 60 °C and even more preferably at 65 °C.

Highly stringent conditions include, for example, hybridizing at 68 °C in 5x SSC/5x Denhardt's solution / 1.0% SDS and washing in 0.2x SSC/0.1% SDS at room temperature. Alternatively, washing may be performed at 42 °C.

The skilled artisan will know which conditions to apply for stringent and highly stringent hybridisation conditions. Additional guidance regarding such conditions is readily available in the art, for example, in Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, N.Y.; and Ausubel et al. (eds.), 1995, Current Protocols in Molecular Biology, (John Wiley & Sons, N.Y.).

Of course, a polynucleotide which hybridizes only to a poly A sequence (such as the 3' terminal poly(A) tract of mRNAs), or to a complementary stretch of T (or U) residues, would not be included in a polynucleotide of the invention used to specifically hybridize to a portion of a nucleic acid of the invention, since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-standed cDNA clone).

### **Obtaining full length DNA from other organisms**

In a typical approach, cDNA libraries constructed from other organisms, e.g. filamentous fungi, in particular from the species *Aspergillus* can  
5 be screened.

For example, *Aspergillus* strains can be screened for homologous PEC7 polynucleotides by Northern blot analysis. Upon detection of transcripts homologous to polynucleotides according to the invention, cDNA  
10 libraries can be constructed from RNA isolated from the appropriate strain, utilizing standard techniques well known to those of skill in the art. Alternatively, a total genomic DNA library can be screened using a probe hybridisable to a PEC7 polynucleotide according to the invention.

Homologous gene sequences can be isolated, for example, by performing PCR using two degenerate oligonucleotide primer pools designed on  
15 the basis of nucleotide sequences as taught herein.

The template for the reaction can be cDNA obtained by reverse transcription of mRNA prepared from strains known or suspected to express a polynucleotide according to the invention. The PCR product can be subcloned and sequenced to ensure that the amplified sequences represent the sequences of a  
20 new PEC7 nucleic acid sequence, or a functional equivalent thereof.

The PCR fragment can then be used to isolate a full length cDNA clone by a variety of known methods. For example, the amplified fragment can be labeled and used to screen a bacteriophage or cosmid cDNA library. Alternatively, the labeled fragment can be used to screen a genomic library.

25 PCR technology also can be used to isolate full length cDNA sequences from other organisms. For example, RNA can be isolated, following standard procedures, from an appropriate cellular or tissue source. A reverse transcription reaction can be performed on the RNA using an oligonucleotide primer specific for the most 5' end of the amplified fragment for the priming of first  
30 strand synthesis.

The resulting RNA/DNA hybrid can then be "tailed" (e.g., with guanines) using a standard terminal transferase reaction, the hybrid can be digested with RNase H, and second strand synthesis can then be primed (e.g., with a poly-C primer). Thus, cDNA sequences upstream of the amplified fragment  
35 can easily be isolated. For a review of useful cloning strategies, see e.g., Sambrook et al., supra; and Ausubel et al., supra.

## Vectors

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a PEC7 protein or a functional equivalent thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. The terms "plasmid" and "vector" can be used interchangeably herein as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vector includes one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operatively linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signal). Such regulatory sequences are described, for example, in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of



host cells and those which direct expression of the nucleotide sequence only in a certain host cell (e.g. tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, encoded by nucleic acids as described herein (e.g. PEC7 proteins, mutant forms of PEC7 proteins, fragments, variants or functional equivalents thereof, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of PEC7 proteins in prokaryotic or eukaryotic cells. For example, PEC7 proteins can be expressed in bacterial cells such as *E. coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression vectors useful in the present invention include chromosomal-, episomal- and virus-derived vectors e.g., vectors derived from bacterial plasmids, bacteriophage, yeast episome, yeast chromosomal elements, viruses such as baculoviruses, papova viruses, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids.

The DNA insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli* lac, trp and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled person. In a specific embodiment, promoters are preferred that are capable of directing a high expression level of pectinases in filamentous fungi. Such promoters are known in the art. The expression constructs may contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the mature transcripts expressed by the constructs will include a translation initiating AUG at the beginning and a termination codon appropriately positioned at the end of the polypeptide to be translated.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, transduction, infection, lipofection, cationic lipid-mediated transfection or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (*Molecular Cloning: A Laboratory Manual*, 2<sup>nd</sup>, ed. Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), Davis et al., *Basic Methods in Molecular Biology* (1986) and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding a PEC7 protein or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g. cells that have incorporated the selectable marker gene will survive, while the other cells die).

Expression of proteins in prokaryotes is often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, e.g. to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase.

As indicated, the expression vectors will preferably contain selectable markers. Such markers include dihydrofolate reductase or neomycin resistance for eukarotic cell culture and tetracycline or ampicilling resistance for culturing in *E. coli* and other bacteria. Representative examples of appropriate host include bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella* typhimurium; fungal cells, such as yeast; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9; animal cells such as CHO, COS and Bowes melanoma; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria are pQE70, pQE60 and PQE-9, available from Qiagen; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNH16A, pNH18A, pNH46A, available from Stratagene; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia. Among preferred eukaryotic vectors are PWLNEO, pSV2CAT, pOG44, pZT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Among known bacterial promoters for use in the present invention include *E. coli* lacI and lacZ promoters, the T3 and T7 promoters, the gpt promoter, the lambda PR, PL promoters and the trp promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous sarcoma virus ("RSV"), and metallothionein promoters, such as the mouse metallothionein-I promoter.

Transcription of the DNA encoding the polypeptides of the present invention by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp that act to increase transcriptional activity of a promoter in a given host cell-type. Examples of enhancers include the SV40 enhancer, which is located on the late side of the replication origin at bp 100 to 270, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signal may be incorporated into the expressed polypeptide. The signals may be endogenous to the polypeptide or they may be heterologous signals.

The polypeptide may be expressed in a modified form, such as

a fusion protein, and may include not only secretion signals but also additional heterologous functional regions. Thus, for instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence in the host cell, during purification or during subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification.

### **Polypeptides according to the invention**

The invention provides an isolated polypeptide having the amino acid sequence according to SEQ ID NO: 3, an amino acid sequence obtainable by expressing the polynucleotide of SEQ ID NO: 1 in an appropriate host, as well as an amino acid sequence obtainable by expressing the polynucleotide sequences of SEQ ID NO: 2 in an appropriate host. Also, a peptide or polypeptide comprising a functional equivalent of the above polypeptides is comprised within the present invention. The above polypeptides are collectively comprised in the term "polypeptides according to the invention"

The terms "peptide" and "oligopeptide" are considered synonymous (as is commonly recognized) and each term can be used interchangeably as the context requires to indicate a chain of at least two amino acids coupled by peptidyl linkages. The word "polypeptide" is used herein for chains containing more than seven amino acid residues. All oligopeptide and polypeptide formulas or sequences herein are written from left to right and in the direction from amino terminus to carboxy terminus. The one-letter code of amino acids used herein is commonly known in the art and can be found in Sambrook, et al. (*Molecular Cloning: A Laboratory Manual*, 2<sup>nd</sup>, ed. Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989)

By "isolated" polypeptide or protein is intended a polypeptide or protein removed from its native environment. For example, recombinantly produced polypeptides and proteins expressed in host cells are considered isolated for the purpose of the invention as are native or recombinant polypeptides which have been substantially purified by any suitable technique such as, for example, the single-step purification method disclosed in Smith and Johnson, Gene 67:31-40 (1988).

The PEC7 pectinase according to the invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or

cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

5 Polypeptides of the present invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides  
10 of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes.

### **Protein fragments**

15 The invention also features biologically active fragments of the polypeptides according to the invention.

Biologically active fragments of a polypeptide of the invention include polypeptides comprising amino acid sequences sufficiently identical to or  
20 derived from the amino acid sequence of the PEC7 protein (e.g., the amino acid sequence of SEQ ID NO: 3), which include fewer amino acids than the full length protein, and exhibit at least one biological activity of the corresponding full-length protein. Typically, biologically active fragments comprise a domain or motif with at least one activity of the PEC7 protein. A biologically active fragment of a protein of  
25 the invention can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the biological activities of the native form of a polypeptide of the invention.

30 The invention also features nucleic acid fragments which encode the above biologically active fragments of the PEC7 protein.

### **Fusion proteins**

35 The proteins of the present invention or functional equivalents thereof, e.g., biologically active portions thereof, can be operatively linked to a non-PEC7 polypeptide (e.g., heterologous amino acid sequences) to form fusion

proteins. As used herein, a PEC7 "chimeric protein" or "fusion protein" comprises a PEC7 polypeptide operatively linked to a non-PEC7 polypeptide. A "PEC7 polypeptide" refers to a polypeptide having an amino acid sequence corresponding to PEC7, whereas a "non-PEC7 polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the PEC7 protein, e.g., a protein which is different from the PEC7 protein and which is derived from the same or a different organism. Within a PEC7 fusion protein the PEC7 polypeptide can correspond to all or a portion of a PEC7 protein. In a preferred embodiment, a PEC7 fusion protein comprises at least one biologically active fragment of a PEC7 protein. In another preferred embodiment, a PEC7 fusion protein comprises at least two biologically active portions of a PEC7 protein. Within the fusion protein, the term "operatively linked" is intended to indicate that the PEC7 polypeptide and the non-PEC7 polypeptide are fused in-frame to each other. The non-PEC7 polypeptide can be fused to the N-terminus or C-terminus of the PEC7 polypeptide.

For example, in one embodiment, the fusion protein is a GST-PEC7 fusion protein in which the PEC7 sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant PEC7. In another embodiment, the fusion protein is a PEC7 protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian and Yeast host cells), expression and/or secretion of PEC7 can be increased through use of a heterologous signal sequence.

In another example, the gp67 secretory sequence of the baculovirus envelope protein can be used as a heterologous signal sequence (*Current Protocols in Molecular Biology*, Ausubel et al., eds., John Wiley & Sons, 1992). Other examples of eukaryotic heterologous signal sequences include the secretory sequences of melittin and human placental alkaline phosphatase (Stratagene; La Jolla, California). In yet another example, useful prokaryotic heterologous signal sequences include the phoA secretory signal (Sambrook et al., *supra*) and the protein A secretory signal (Pharmacia Biotech; Piscataway, New Jersey).

A signal sequence can be used to facilitate secretion and isolation of a protein or polypeptide of the invention. Signal sequences are typically characterized by a core of hydrophobic amino acids which are generally cleaved from the mature protein during secretion in one or more cleavage events. Such signal peptides contain processing sites that allow cleavage of the signal

sequence from the mature proteins as they pass through the secretory pathway. The signal sequence directs secretion of the protein, such as from a eukaryotic host into which the expression vector is transformed, and the signal sequence is subsequently or concurrently cleaved. The protein can then be readily purified  
5 from the extracellular medium by art recognized methods. Alternatively, the signal sequence can be linked to the protein of interest using a sequence which facilitates purification, such as with a GST domain. Thus, for instance, the sequence encoding the polypeptide may be fused to a marker sequence, such as a sequence encoding a peptide, which facilitates purification of the fused  
10 polypeptide. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (Qiagen, Inc.), among others, many of which are commercially available. As described in *Gentz et al, Proc. Natl. Acad. Sci. USA 86:821-824 (1989)*, for instance, hexa-histidine provides for convenient purification of the fusion protein.  
15 The HA tag is another peptide useful for purification which corresponds to an epitope derived of influenza hemagglutinin protein, which has been described by Wilson *et al., Cell 37:767 (1984)*, for instance.

Preferably, a PEC7 chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA  
20 fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In  
25 another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene  
30 sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel *et al.* John Wiley & Sons: 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g, a GST polypeptide). A PEC7-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the PEC7  
35 protein.

### **Functional equivalents**

The terms "functional equivalents" and "functional variants" are used interchangeably herein. Functional equivalents of PEC7 DNA are isolated DNA fragments that encode a polypeptide that exhibits a particular function of the PEC7 *A. niger* pectinase as defined herein. A functional equivalent of a PEC7 polypeptide according to the invention is a polypeptide that exhibits at least one function of an *A. niger* pectinase as defined herein. Functional equivalents therefore also encompass biologically active fragments.

Functional protein or polypeptide equivalents may contain only conservative substitutions of one or more amino acids of SEQ ID NO: 3 or substitutions, insertions or deletions of non-essential amino acids. Accordingly, a non-essential amino acid is a residue that can be altered in SEQ ID NO: 3 without substantially altering the biological function. For example, amino acid residues that are conserved among the PEC7 proteins of the present invention, are predicted to be particularly unamenable to alteration. Furthermore, amino acids conserved among the PEC7 proteins according to the present invention and other pectinases are not likely to be amenable to alteration.

The term "conservative substitution" is intended to mean that a substitution in which the amino acid residue is replaced with an amino acid residue having a similar side chain. These families are known in the art and include amino acids with basic side chains (e.g. lysine, arginine and histidine), acidic side chains (e.g. aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).

Functional nucleic acid equivalents may typically contain silent mutations or mutations that do not alter the biological function of encoded polypeptide. Accordingly, the invention provides nucleic acid molecules encoding PEC7 proteins that contain changes in amino acid residues that are not essential for a particular biological activity. Such PEC7 proteins differ in amino acid sequence from SEQ ID NO: 3 yet retain at least one biological activity. In one embodiment the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises a substantially homologous amino acid sequence of at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%,



95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence shown in SEQ ID NO: 3.

For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J.U. et al., Science 247:1306-1310 (1990) wherein the authors indicate that there are two main approaches for studying the tolerance of an amino acid sequence to change. The first method relies on the process of evolution, in which mutations are either accepted or rejected by natural selection. The second approach uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene and selects or screens to identify sequences that maintain functionality. As the authors state, these studies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which changes are likely to be permissive at a certain position of the protein. For example, most buried amino acid residues require non-polar side chains, whereas few features of surface side chains are generally conserved. Other such phenotypically silent substitutions are described in Bowie et al, supra, and the references cited therein.

An isolated nucleic acid molecule encoding a PEC7 protein homologous to the protein according to SEQ ID NO: 3 can be created by introducing one or more nucleotide substitutions, additions or deletions into the coding nucleotide sequences according to SEQ ID NO: 1 or SEQ ID NO: 2 such that one or more amino acid substitutions, deletions or insertions are introduced into the encoded protein. Such mutations may be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis.

The term "functional equivalents" also encompasses orthologues of the *A. niger* PEC7 protein. Orthologues of the *A. niger* PEC7 protein are proteins that can be isolated from other strains or species and possess a similar or identical biological activity. Such orthologues can readily be identified as comprising an amino acid sequence that is substantially homologous to SEQ ID NO: 3.

As defined herein, the term "substantially homologous" refers to a first amino acid or nucleotide sequence which contains a sufficient or minimum number of identical or equivalent (e.g., with similar side chain) amino acids or nucleotides to a second amino acid or nucleotide sequence such that the first and the second amino acid or nucleotide sequences have a common domain. For example, amino acid or nucleotide sequences which contain a common domain having about 60%, preferably 65%, more preferably 70%, even more preferably

75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity or more are defined herein as sufficiently identical.

Also, nucleic acids encoding other PEC7 family members, which thus have a nucleotide sequence that differs from SEQ ID NO: 1 or SEQ ID NO: 2, are within the scope of the invention. Moreover, nucleic acids encoding PEC7 proteins from different species which thus have a nucleotide sequence which differs from SEQ ID NO: 1 or SEQ ID NO: 2 are within the scope of the invention.

Nucleic acid molecules corresponding to variants (e.g. natural allelic variants) and homologues of the PEC7 DNA of the invention can be isolated based on their homology to the PEC7 nucleic acids disclosed herein using the cDNAs disclosed herein or a suitable fragment thereof, as a hybridisation probe according to standard hybridisation techniques preferably under highly stringent hybridisation conditions.

In addition to naturally occurring allelic variants of the PEC7 sequence, the skilled person will recognise that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO: 1 or SEQ ID NO: 2 thereby leading to changes in the amino acid sequence of the PEC7 protein without substantially altering the function of the PEC7 protein.

In another aspect of the invention, improved PEC7 proteins are provided. Improved PEC7 proteins are proteins wherein at least one biological activity is improved. Such proteins may be obtained by randomly introducing mutations along all or part of the PEC7 coding sequence, such as by saturation mutagenesis, and the resulting mutants can be expressed recombinantly and screened for biological activity. For instance, the art provides for standard assays for measuring the enzymatic activity of pectinases and thus improved proteins may easily be selected.

In a preferred embodiment the PEC7 protein has an amino acid sequence according to SEQ ID NO: 3. In another embodiment, the PEC7 polypeptide is substantially homologous to the amino acid sequence according to SEQ ID NO: 3 and retains at least one biological activity of a polypeptide according to SEQ ID NO: 3, yet differs in amino acid sequence due to natural variation or mutagenesis as described above.

In a further preferred embodiment, the PEC7 protein has an amino acid sequence encoded by an isolated nucleic acid fragment capable of hybridising to a nucleic acid according to SEQ ID NO: 1 or SEQ ID NO: 2, preferably under highly stringent hybridisation conditions.

Accordingly, the PEC7 protein is a protein which comprises an amino acid sequence at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence shown in SEQ ID NO: 3 and retains at least one functional activity of the polypeptide according to SEQ ID NO: 3.

Functional equivalents of a protein according to the invention can also be identified e.g. by screening combinatorial libraries of mutants, e.g. truncation mutants, of the protein of the invention for pectinase activity. In one embodiment, a variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level. A variegated library of variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential protein sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display). There are a variety of methods that can be used to produce libraries of potential variants of the polypeptides of the invention from a degenerate oligonucleotide sequence. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang (1983) Tetrahedron 39:3; Itakura et al. (1984) Annu. Rev. Biochem. 53:323; Itakura et al. (1984) Science 198:1056; Ike et al. (1983) Nucleic Acid Res. 11:477).

In addition, libraries of fragments of the coding sequence of a polypeptide of the invention can be used to generate a variegated population of polypeptides for screening a subsequent selection of variants. For example, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of the coding sequence of interest with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal and internal fragments of various sizes of the protein of interest.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations of truncation, and for screening cDNA libraries for gene products having a selected property. The most widely used techniques, which are amenable to high through-put analysis, for

screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify variants of a protein of the invention (Arkin and Yourvan (1992) Proc. Natl. Acad. Sci. USA 89:7811-7815; Delgrave et al. (1993) Protein Engineering 6(3):327-331).

In addition to the PEC7 gene sequence shown in SEQ ID NO: 1, it will be apparent for the person skilled in the art that DNA sequence polymorphisms that may lead to changes in the amino acid sequence of the PEC7 protein may exist within a given population. Such genetic polymorphisms may exist in cells from different populations or within a population due to natural allelic variation. Allelic variants may also include functional equivalents.

Fragments of a polynucleotide according to the invention may also comprise polynucleotides not encoding functional polypeptides. Such polynucleotides may function as probes or primers for a PCR reaction.

Nucleic acids according to the invention irrespective of whether they encode functional or non-functional polypeptides, can be used as hybridization probes or polymerase chain reaction (PCR) primers. Uses of the nucleic acid molecules of the present invention that do not encode a polypeptide having a PEC7 activity include, inter alia, (1) isolating the gene encoding the PEC7 protein, or allelic variants thereof from a cDNA library e.g. from other organisms than *A. niger*; (2) in situ hybridization (e.g. FISH) to metaphase chromosomal spreads to provide precise chromosomal location of the PEC7 gene as described in Verma et al., Human Chromosomes: a Manual of Basic Techniques, Pergamon Press, New York (1988); (3) Northern blot analysis for detecting expression of PEC7 mRNA in specific tissues and/or cells and 4) probes and primers that can be used as a diagnostic tool to analyse the presence of a nucleic acid hybridisable to the PEC7 probe in a given biological (e.g. tissue) sample.

Also encompassed by the invention is a method of obtaining a functional equivalent of a PEC7 gene or cDNA. Such a method entails obtaining a labelled probe that includes an isolated nucleic acid which encodes all or a portion of the sequence according to SEQ ID NO: 3 or a variant thereof; screening a

nucleic acid fragment library with the labelled probe under conditions that allow hybridisation of the probe to nucleic acid fragments in the library, thereby forming nucleic acid duplexes, and preparing a full-length gene sequence from the nucleic acid fragments in any labelled duplex to obtain a gene related to the PEC7 gene.

5 In one embodiment, a PEC7 nucleic acid of the invention is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more homologous to a nucleic acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 2 or the complement thereof.

10 In another preferred embodiment a PEC7 polypeptide of the invention is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more homologous to the amino acid sequence shown in SEQ ID NO: 3.

### Host cells

15 In another embodiment, the invention features cells, e.g., transformed host cells or recombinant host cells that contain a nucleic acid encompassed by the invention. A "transformed cell" or "recombinant cell" is a cell into which (or into an ancestor of which) has been introduced, by means of  
20 recombinant DNA techniques, a nucleic acid according to the invention. Both prokaryotic and eukaryotic cells are included, e.g., bacteria, fungi, yeast, and the like, especially preferred are cells from filamentous fungi, in particular *Aspergillus niger*.

25 A host cell can be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in a specific, desired fashion. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may facilitate optimal functioning of the protein.

Various host cells have characteristic and specific mechanisms for post-translational processing and modification of proteins and gene products.  
30 Appropriate cell lines or host systems familiar to those of skill in the art of molecular biology and/or microbiology can be chosen to ensure the desired and correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells that possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product can  
35 be used. Such host cells are well known in the art.

Host cells also include, but are not limited to, mammalian cell lines such as CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and

choroid plexus cell lines.

If desired, the polypeptides according to the invention can be produced by a stably-transfected cell line. A number of vectors suitable for stable transfection of mammalian cells are available to the public, methods for  
5 constructing such cell lines are also publicly known, e.g., in Ausubel et al. (supra).

### **Antibodies**

The invention further features antibodies, such as monoclonal or  
10 polyclonal antibodies, that specifically bind PEC7 proteins according to the invention.

As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')<sub>2</sub> fragments) which are capable of  
15 specifically binding to PEC7 protein. Fab and F(ab')<sub>2</sub> fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding of an intact antibody (Wahl *et al.*, *J. Nucl. Med.* 24:316-325 (1983)). Thus, these fragments are preferred.

The antibodies of the present invention may be prepared by any  
20 of a variety of methods. For example, cells expressing the PEC7 protein or an antigenic fragment thereof can be administered to an animal in order to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of PEC7 protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in  
25 order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or PEC7 protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology (Kohler *et al.*, *Nature* 256:495 (1975); Kohler *et al.*, *Eur. J. Immunol.* 6:511 (1976);  
30 Hammerling *et al.*, In: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-681 (1981)). In general, such procedures involve immunizing an animal (preferably a mouse) with a PEC7 protein antigen or, with a PEC7 protein expressing cell. The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in  
35 accordance with the present invention; however, it is preferably to employ the parent myeloma cell line (SP<sub>2</sub>O), available from the American Type Culture Collection, Rockville, Maryland. After fusion, the resulting hybridoma cells are

selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands *et al.* (*Gastro-enterology* 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the PEC7 protein antigen. In general, the polypeptides can be coupled to a carrier protein, such as KLH, as described in Ausubel *et al.*, supra, mixed with an adjuvant, and injected into a host mammal.

In particular, various host animals can be immunized by injection of a polypeptide of interest. Examples of suitable host animals include rabbits, mice, guinea pigs, and rats. Various adjuvants can be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), adjuvant mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals.

Such antibodies can be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD, and any subclass thereof. The hybridomas producing the mAbs of this invention can be cultivated *in vitro* or *in vivo*.

Once produced, polyclonal or monoclonal antibodies are tested for specific recognition of a PEC7 polypeptide or functional equivalent thereof in an immunoassay, such as a Western blot or immunoprecipitation analysis using standard techniques, e.g., as described in Ausubel *et al.*, supra. Antibodies that specifically bind to PEC7 proteins or functional equivalents thereof are useful in the invention. For example, such antibodies can be used in an immunoassay to detect PEC7 in pathogenic or non-pathogenic strains of *Aspergillus* (e.g., in *Aspergillus* extracts).

Preferably, antibodies of the invention are produced using fragments of the PEC7 polypeptides that appear likely to be antigenic, by criteria such as high frequency of charged residues. For example, such fragments may be generated by standard techniques of PCR, and then cloned into the pGEX expression vector (Ausubel *et al.*, supra). Fusion proteins may then be expressed in *E. coli* and purified using a glutathione agarose affinity matrix as described in Ausubel, *et al.*, supra. If desired, several (e.g., two or three) fusions can be generated for each protein, and each fusion can be injected into at least two rabbits. Antisera can be raised by injections in a series, typically including at least

three booster injections. Typically, the antisera are checked for their ability to immunoprecipitate a recombinant PEC7 polypeptide or functional equivalents thereof whereas unrelated proteins may serve as a control for the specificity of the immune reaction.

5                   Alternatively, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778 and 4,704,692) can be adapted to produce single chain antibodies against a PEC7 polypeptide or functional equivalents thereof. Kits for generating and screening phage display libraries are commercially available e.g. from Pharmacia.

10                   Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, U.S. Patent No. 5,223, 409; PCT Publication No. WO 92/18619; PCT Publication No. WO 91/17271; PCT Publication No. WO 20791; PCT Publication No. WO 92/20791; PCT Publication No. WO 15 92/15679; PCT Publication No. WO 93/01288; PCT Publication No. WO 92/01047; PCT Publication No. WO 92/09690; PCT Publication No. WO 90/02809; Fuchs et al. (1991) *Bio/Technology* 9:1370-1372; Hay et al. (1992) *Hum. Antibod. Hybridomas* 3:81-85; Huse et al. (1989) *Science* 246:1275-1281; Griffiths et al. (1993) *EMBO J.* 12:725-734.

20                   Polyclonal and monoclonal antibodies that specifically bind PEC7 polypeptides or functional equivalents thereof can be used, for example, to detect expression of a PEC7 gene or a functional equivalent thereof e.g. in another strain of *Aspergillus*. For example, PEC7 polypeptide can be readily detected in conventional immunoassays of *Aspergillus* cells or extracts. Examples 25 of suitable assays include, without limitation, Western blotting, ELISAs, radioimmune assays, and the like.

By "specifically binds" is meant that an antibody recognizes and binds a particular antigen, e.g., a PEC7 polypeptide, but does not substantially recognize and bind other unrelated molecules in a sample.

30                   Antibodies can be purified, for example, by affinity chromatography methods in which the polypeptide antigen is immobilized on a resin.

35                   An antibody directed against a polypeptide of the invention (e.g., monoclonal antibody) can be used to isolate the polypeptide by standard techniques, such as affinity chromatography or immunoprecipitation. Moreover, such an antibody can be used to detect the protein (e.g., in a cellular lysate or cell



supernatant) in order to evaluate the abundance and pattern of expression of the polypeptide. The antibodies can also be used diagnostically to monitor protein levels in cells or tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen or in the diagnosis of

5 Aspergillosis..

Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable  
10 enzymes include horseradish peroxidase, alkaline phosphatase,  $\beta$ -galactosidase, or acetylcholinesterase; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials  
15 include luciferase, luciferin, and aequorin, and examples of suitable radioactive materials include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{35}\text{S}$  or  $^3\text{H}$ .

Preferred epitopes encompassed by the antigenic peptide are regions that are located on the surface of the protein, e.g., hydrophilic regions. Hydrophobicity plots of the proteins of the invention can be used to identify  
20 hydrophilic regions.

The antigenic peptide of a protein of the invention comprises at least 7 (preferably 10, 15, 20, or 30) contiguous amino acid residues of the amino acid sequence of SEQ ID NO: 3 and encompasses an epitope of the protein such that an antibody raised against the peptide forms a specific immune complex with  
25 the protein.

Preferred epitopes encompassed by the antigenic peptide are regions of PEC7 that are located on the surface of the protein, e.g., hydrophilic regions, hydrophobic regions, alpha regions, beta regions, coil regions, turn regions and flexible regions.

30

**Immunoassays**

Qualitative or quantitative determination of a polypeptide according to the present invention in a biological sample can occur using any art-  
35 known method. Antibody-based techniques provide special advantages for assaying specific polypeptide levels in a biological sample.

In these, the specific recognition is provided by the primary

antibody (polyclonal or monoclonal) but the secondary detection system can utilize fluorescent, enzyme, or other conjugated secondary antibodies. As a result, an immunocomplex is obtained.

- Accordingly, the invention provides a method for diagnosing whether a certain organism is infected with *Aspergillus* comprising the steps of:
- Isolating a biological sample from said organism suspected to be infected with *Aspergillus*,
  - reacting said biological sample with an antibody according to the invention,
  - determining whether immunocomplexes are formed.

Tissues can also be extracted, e.g., with urea and neutral detergent, for the liberation of protein for Western-blot or dot/slot assay. This technique can also be applied to body fluids.

Other antibody-based methods useful for detecting PEC7 gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). For example, PEC7-specific monoclonal antibodies can be used both as an immunoabsorbent and as an enzyme-labeled probe to detect and quantify the PEC7 protein. The amount of PEC7 protein present in the sample can be calculated by reference to the amount present in a standard preparation using a linear regression computer algorithm. In another ELISA assay, two distinct specific monoclonal antibodies can be used to detect PEC7 protein in a biological fluid. In this assay, one of the antibodies is used as the immuno-absorbent and the other as the enzyme-labeled probe.

The above techniques may be conducted essentially as a "one-step" or "two-step" assay. The "one-step" assay involves contacting PEC7 protein with immobilized antibody and, without washing, contacting the mixture with the labeled antibody. The "two-step" assay involves washing before contacting the mixture with the labeled antibody. Other conventional methods may also be employed as suitable. It is usually desirable to immobilize one component of the assay system on a support, thereby allowing other components of the system to be brought into contact with the component and readily removed from the sample.

Suitable enzyme labels include, for example, those from the oxidase group, which catalyze the production of hydrogen peroxide by reacting with substrate. Activity of an oxidase label may be assayed by measuring the concentration of hydrogen peroxide formed by the enzyme-labelled antibody/substrate reaction.

Besides enzymes, other suitable labels include radioisotopes,

such as iodine ( $^{125}\text{I}$ ,  $^{127}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulphur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99\text{m}}\text{Tc}$ ), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

Specific binding of a test compound to a PEC7 polypeptide can be detected, for example, in vitro by reversibly or irreversibly immobilizing the PEC7 polypeptide on a substrate, e.g., the surface of a well of a 96-well polystyrene microtitre plate. Methods for immobilizing polypeptides and other small molecules are well known in the art. For example, the microtitre plates can be coated with a PEC7 polypeptide by adding the polypeptide in a solution (typically, at a concentration of 0.05 to 1 mg/ml in a volume of 1-100  $\mu\text{l}$ ) to each well, and incubating the plates at room temperature to 37  $^{\circ}\text{C}$  for 0.1 to 36 hours. Polypeptides that are not bound to the plate can be removed by shaking the excess solution from the plate, and then washing the plate (once or repeatedly) with water or a buffer. Typically, the polypeptide is contained in water or a buffer. The plate is then washed with a buffer that lacks the bound polypeptide. To block the free protein-binding sites on the plates, the plates are blocked with a protein that is unrelated to the bound polypeptide. For example, 300  $\mu\text{l}$  of bovine serum albumin (BSA) at a concentration of 2 mg/ml in Tris-HCl is suitable. Suitable substrates include those substrates that contain a defined cross-linking chemistry (e.g., plastic substrates, such as polystyrene, styrene, or polypropylene substrates from Corning Costar Corp. (Cambridge, MA), for example) . If desired, a beaded particle, e.g., beaded agarose or beaded sepharose, can be used as the substrate.

Binding of the test compound to the polypeptides according to the invention can be detected by any of a variety of artknown methods. For example, a specific antibody can be used in an immunoassay. If desired, the antibody can be labeled (e.g., fluorescently or with a radioisotope) and detected directly (see, e.g., West and McMahon, J. Cell Biol. 74:264, 1977). Alternatively, a second antibody can be used for detection (e.g., a labeled antibody that binds the Fc portion of an anti-AN97 antibody). In an alternative detection method, the PEC7 polypeptide is labeled, and the label is detected (e.g., by labeling a PEC7 polypeptide with a radioisotope, fluorophore, chromophore, or the like). In still another method, the PEC7 polypeptide is produced as a fusion protein with a protein that can be detected optically, e.g., green fluorescent protein (which can be detected under UV light). In an alternative method, the PEC7 polypeptide can be covalently attached to or fused with an enzyme having a detectable enzymatic

activity, such as horse radish peroxidase, alkaline phosphatase, a-galactosidase, or glucose oxidase. Genes encoding all of these enzymes have been cloned and are readily available for use by those of skill in the art. If desired, the fusion protein can include an antigen, and such an antigen can be detected and measured with a polyclonal or monoclonal antibody using conventional methods. Suitable antigens include enzymes (e.g., horse radish peroxidase, alkaline phosphatase, and a-galactosidase) and non-enzymatic polypeptides (e.g., serum proteins, such as BSA and globulins, and milk proteins, such as caseins).

10 **Epitopes, antigens and immunogens.**

In another aspect, the invention provides a peptide or polypeptide comprising an epitope-bearing portion of a polypeptide of the invention. The epitope of this polypeptide portion is an immunogenic or antigenic epitope of a polypeptide of the invention. An "immunogenic epitope" is defined as a part of a protein that elicits an antibody response when the whole protein is the immunogen. These immunogenic epitopes are believed to be confined to a few loci on the molecule. On the other hand, a region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." The number of immunogenic epitopes of a protein generally is less than the number of antigenic epitopes. See, for instance, Geysen, H. M. et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1984).

As to the selection of peptides or polypeptides bearing an antigenic epitope (i.e., that contain a region of a protein molecule to which an antibody can bind), it is well known in that art that relatively short synthetic peptides that mimic part of a protein sequence are routinely capable of eliciting an antiserum that reacts with the partially mimicked protein. See, for instance, Sutcliffe, J. G. et al., Science 219:660-666 (1984). Peptides capable of eliciting protein-reactive sera are frequently represented in the primary sequence of a protein, can be characterized by a set of simple chemical rules, and are confined neither to immunodominant regions of intact proteins (i.e., immunogenic epitopes) nor to the amino or carboxyl terminals. Peptides that are extremely hydrophobic and those of six or fewer residues generally are ineffective at inducing antibodies that bind to the mimicked protein; longer, soluble peptides, especially those containing proline residues, usually are effective. Sutcliffe et al., supra, at 661. For instance, 18 of 20 peptides designed according to these guidelines, containing 8-

39 residues covering 75% of the sequence of the influenza virus hemagglutinin HA1 polypeptide chain, induced antibodies that reacted with the HA1 protein or intact virus; and 12/12 peptides from the MuLV polymerase and 18/18 from the rabies glycoprotein induced antibodies that precipitated the respective proteins.

5                   Antigenic epitope-bearing peptides and polypeptides of the invention are therefore useful to raise antibodies, including monoclonal antibodies, that bind specifically to a polypeptide of the invention. Thus, a high proportion of hybridomas obtained by fusion of spleen cells from donors immunized with an antigen epitope-bearing peptide generally secrete antibody reactive with the  
10 native protein. Sutcliffe et al., supra, at 663. The antibodies raised by antigenic epitope bearing peptides or polypeptides are useful to detect the mimicked protein, and antibodies to different peptides may be used for tracking the fate of various regions of a protein precursor which undergoes posttranslation processing. The peptides and anti-peptide antibodies may be used in a variety of  
15 qualitative or quantitative assays for the mimicked protein, for instance in competition assays since it has been shown that even short peptides (e.g., about 9 amino acids) can bind and displace the larger peptides in immunoprecipitation assays. See, for instance, Wilson, I.A. et al., Cell 37:767-778 at 777 (1984). The anti-peptide antibodies of the invention also are useful for purification of the  
20 mimicked protein, for instance, by adsorption chromatography using methods well known in the art.

                  Antigenic epitope-bearing peptides and polypeptides of the invention designed according to the above guidelines preferably contain a sequence of at least seven, more preferably at least nine and most preferably  
25 between about 15 to about 30 amino acids contained within the amino acid sequence of a polypeptide of the invention. However, peptides or polypeptides comprising a larger portion of an amino acid sequence of a polypeptide of the invention, containing about 30 to about 50 amino acids, or any length up to and including the entire amino acid sequence of a polypeptide of the invention, also  
30 are considered epitope-bearing peptides or polypeptides of the invention and also are useful for inducing antibodies that react with the mimicked protein. Preferably, the amino acid sequence of the epitope-bearing peptide is selected to provide substantial solubility in aqueous solvents (i.e., the sequence includes relatively hydrophilic residues and highly hydrophobic sequences are preferably avoided);  
35 and sequences containing proline residues are particularly preferred.

                  The epitope-bearing peptides and polypeptides of the invention

may be produced by any conventional means for making peptides or polypeptides including recombinant means using nucleic acid molecules of the invention. For instance, a short epitope-bearing amino acid sequence may be fused to a larger polypeptide which acts as a carrier during recombinant production and

5 purification, as well as during immunization to produce anti-peptide antibodies.

Epitope-bearing peptides also may be synthesized using known methods of chemical synthesis. For instance, Houghten has described a simple method for synthesis of large numbers of peptides, such as 10-20 mg of 248 different 13 residue peptides representing single amino acid variants of a segment  
10 of the HAI polypeptide which were prepared and characterized (by ELISA-type binding studies) in less than four weeks. Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985). This "Simultaneous Multiple Peptide Synthesis (SMPS)" process is further described in U.S. Patent No. 4,631,211 to Houghten et al. (1986). In this procedure the individual resins for the solid-phase synthesis of  
15 various peptides are contained in separate solvent-permeable packets, enabling the optimal use of the many identical repetitive steps involved in solid-phase methods.

A completely manual procedure allows 500-1000 or more syntheses to be conducted simultaneously. Houghten et al., supra, at 5134.

20 Epitope-bearing peptides and polypeptides of the invention are used to induce antibodies according to methods well known in the art. See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow, M. et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle, F.J. et al., J. Gen. Virol. 66:2347-2354 (1985).

25 Generally, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling of the peptide to a macromolecular carrier, such as keyhole limpet hemocyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine may be coupled to carrier using a linker such as maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), while other  
30 peptides may be coupled to carrier using a more general linking agent such as glutaraldehyde.

Animals such as rabbits, rats and mice are immunized with either free or carriercoupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 ug peptide or carrier  
35 protein and Freund's adjuvant. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide

antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the  
5 selected antibodies according to methods well known in the art.

Immunogenic epitope-bearing peptides of the invention, i.e., those parts of a protein that elicit an antibody response when the whole protein is the immunogen, are identified according to methods known in the art. For instance, Geysen et al., 1984, supra, discloses a procedure for rapid concurrent  
10 synthesis on solid supports of hundreds of peptides of sufficient purity to react in an enzyme-linked immunosorbent assay. Interaction of synthesized peptides with antibodies is then easily detected without removing them from the support. In this manner a peptide bearing an immunogenic epitope of a desired protein may be identified routinely by one of ordinary skill in the art. For instance, the  
15 immunologically important epitope in the coat protein of foot-and-mouth disease virus was located by Geysen et al. with a resolution of seven amino acids by synthesis of an overlapping set of all 208 possible hexapeptides covering the entire 213 amino acid sequence of the protein. Then, a complete replacement set of peptides in which all 20 amino acids were substituted in turn at every position  
20 within the epitope were synthesized, and the particular amino acids conferring specificity for the reaction with antibody were determined. Thus, peptide analogs of the epitope-bearing peptides of the invention can be made routinely by this method. U.S. Patent No. 4,708,781 to Geysen (1987) further describes this method of identifying a peptide bearing an immunogenic epitope of a desired  
25 protein.

Further still, U.S. Patent No. 5,194,392 to Geysen (1990) describes a general method of detecting or determining the sequence of monomers (amino acids or other compounds) which is a topological equivalent of the epitope (i.e., a "mimotope") which is complementary to a particular paratope  
30 (antigen binding site) of an antibody of interest. More generally, U.S. Patent No. 4,433,092 to Geysen (1989) describes a method of detecting or determining a sequence of monomers which is a topographical equivalent of a ligand which is complementary to the ligand binding site of a particular receptor of interest. Similarly, U.S. Patent  
35 No. 5,480,971 to Houghten, R. A. et al. (1996) on Peralkylated Oligopeptide Mixtures discloses linear C1-C7-alkyl peralkylated oligopeptides and sets and

libraries of such peptides, as well as methods for using such oligopeptide sets and libraries for determining the sequence of a peralkylated oligopeptide that preferentially binds to an acceptor molecule of interest. Thus, non-peptide analogs of the epitope-bearing peptides of the invention also can be made routinely by these methods.

### **Use of PEC7 pectinases in industrial processes**

Pectins and pectinases play an important role in the food industry. Pectinases are used in the production of fruit and vegetable juices and purees, and in the extraction of useful components, like aroma compounds, or even pharmaceuticals, from plant materials.

One of the main application of pectinases is in the production of clear fruit and vegetable juice. The production of juices from fruit and vegetables typically involves, after an optional washing step, grinding, crushing or otherwise destroying the integrity of the fruit or vegetables thus obtaining a fruit or vegetable pulp. Subsequently, the pulp may be treated with enzymes to decrease soluble pectin, a process generally referred to as maceration. After maceration, the pulp is ready for pressing, leading to a juice fraction and a residue fraction, the latter being referred to as the pomace. The juice obtained after pressing is usually pasteurised, optionally with recovery of the aroma, which may then be added back at the end of the process. In order to obtain a clear concentrate, the pasteurised juice is enzymatically depectinized with the aid of pectinases, optionally pre-concentrated, filtrated, optionally ultra-filtrated and concentrated to obtain a clear concentrate or juice which is ready for shipping and/or blending to obtain a clear apple juice for the consumer market

PEC7 pectinases are useful in all production processes in which the integrity of the cell wall should be destroyed in order to release materials from the inside of the cells, or from the cell walls.

Pectinases can also be used to destroy the connection between cells without affecting the integrity of the separate cells. When cells should remain intact, e.g. in the preparation of potato puree PEC7 pectinases can be used to release the structural connection between the cells.

PEC7 pectinases are also able to decrease the water-binding and hence the viscosity of pectin-containing slurries, e.g. fruit or vegetable pulps, which improves the pressability/processability of the pulp.

PEC7 pectinases are able to clarify cloudy juices. Attacking the



outer pectin layer of the cloud particles changes the charge of the particles, thus promoting the aggregation of the particles.

PEC7 pectinases may also be used in the retting of flax (to release the cellulose fibres from the plant tissue) and the scouring of cotton (to increase the water absorbance and dye uptake of the cotton fibres).

Plant and pectin-containing materials include plant pulp, parts of plants and plant extracts. In the context of this invention an extract from a plant material is any substance which can be derived from plant material by extraction (mechanical and/or chemical), processing or by other separation techniques. The extract may be juice, nectar, base, or concentrates made thereof. The plant material may comprise or be derived from vegetables, e.g., carrots, celery, onions, legumes or leguminous plants (soy, soybean, peas) or fruit, e.g., pome or seed fruit (apples, pears, quince etc.), grapes, tomatoes, citrus (orange, lemon, lime, mandarin), melons, prunes, cherries, black currants, redcurrants, raspberries, strawberries, cranberries, pineapple and other tropical fruits, trees and parts thereof (e.g. pollen, from pine trees).

Fruit juice that needs to be filtrated after or during processing tends to clot the filters after some time. This is due to the inability of certain enzymes to properly digest fruit polysaccharides which causes the fouling of the filters.. Use of the enzymes according to the invention prevents fouling of filters because of the unique specificity of the PEC7 pectinase.

PEC7 pectinases may conveniently be produced in microorganisms. Microbial pectinases are available from a variety of sources; Bacillus spec. are a common source of bacterial enzymes, whereas fungal enzymes are commonly produced in Aspergillus spec.

In the above processes, it is advantageous to use pectinases that are obtained by recombinant DNA techniques. Such recombinant enzymes have a number of advantages over their traditionally purified counterparts. Recombinant enzymes may be produced at a low cost price, high yield, free from contaminating agents like bacteria or viruses but also free from bacterial toxins or contaminating other enzyme activities.

The polypeptides of the invention may be used to treat plant material including plant pulp and plant extracts. For example, they may be used to treat apple pulp and/or raw juice during the production of apple juice. They may also be used to treat liquid or solid foodstuffs or edible foodstuff ingredients.

Conveniently the polypeptide of the invention is combined with suitable (solid or liquid) carriers or diluents including buffers to produce a composition or enzyme preparation. The polypeptide is typically stably formulated either in liquid or dry form. Typically, the product is made as a composition which will optionally include, for example, a stabilising buffer and/or preservative. The compositions may also include other enzymes capable of digesting plant material or pectin, for example other pectinases such as an endo-arabinanase, rhamnogalacturonases, and/or polygalacturonase. For certain applications, immobilization of the enzyme on a solid matrix or incorporation on or into solid carrier particles may be preferred. The composition may also include a variety of other plant material-degrading enzymes, for example cellulases and other pectinases.

The polypeptides and compositions of the invention may therefore be used in a method of processing plant material to degrade or modify the pectin constituents of the cell walls of the plant material

Typically, the polypeptides of the invention are used as a composition/ enzyme preparation as described above. The composition will generally be added to plant pulp obtainable by, for example mechanical processing such as crushing or milling plant material. Incubation of the composition with the plant will typically be carried out for a time of from 10 minutes to 5 hours, such as 30 minutes to 2 hours, preferably for about 1 hour. The processing temperature is preferably 10-55°C, e.g. from 15 to 25°C, optimally about 20°C and one can use 10-300g, preferably 30-70g, optimally about 50g of enzyme per ton of material to be treated. All the enzyme(s) or their compositions used may be added sequentially or at the same time to the plant pulp. Depending on the composition of the enzyme preparation the plant material may first be macerated (e.g. to a purée) or liquefied. Using the polypeptides of the invention processing parameters such as the yield of the extraction, viscosity of the extract and/or quality of the extract can be improved.

Alternatively, or in addition to the above, a polypeptide of the invention may be added to the raw juice obtained from pressing or liquefying the plant pulp. Treatment of the raw juice may be carried out in a similar manner to the plant pulp in respect of dosage, temperature and holding time. Again, other enzymes than pectinases may be included.

A composition containing a polypeptide of the invention may also be used during the preparation of fruit or vegetable purees. The end product of these processes is typically heat-treated at 85°C for a time of from 1 minute to

1 hour, under conditions to partially or fully inactivate the polypeptides of the invention.

Due to the highly specific action on pectins the polypeptides of the invention may also be used to prepare pectins with modified characteristics, e.g. modified gelation capacities for specific applications.

The polypeptides of the invention may be added to animal feeds rich in pectin, e.g. soy-containing food, to improve the breakdown of the plant cell wall leading to improved utilisation of the plant nutrients by the animal. The polypeptides of the invention may be added to the feed or silage if pre-soaking or wet diets are preferred. Advantageously, the polypeptides of the invention may continue to degrade pectins in the feed in vivo. Fungal derived polypeptides of the invention in particular generally have lower pH optima and are capable of releasing important nutrients in such acidic environments as the stomach of an animal. The invention thus also contemplates (e.g. animal) feeds or foodstuffs comprising one or more polypeptides of the invention.

A PEC7 pectinase may also be advantageously used during the production of milk substitutes (or replacers) from soy bean. These milk substitutes can be consumed by both humans and animals. A typical problem during the preparation of these milk substitutes is the high viscosity of the soy bean slurry, resulting in the need for an undesirable dilution of the slurry to a concentration of dry solids of 10 to 15%. An enzyme preparation containing a polypeptide of the invention can be added to, or during the processing of, the slurry, enabling processing at a higher concentration (typically 40 to 50%) dry solids. Addition of pectinases of the invention to a soy suspension as described in WO 95/29598 results in a decrease in waterbinding and a concomitant decrease in viscosity of the slurry.

The enzyme may also be used in the preparation of savoury product(s), e.g. from soy bean.

The invention also relates to the use of the PEC7 pectinase according to the invention in a selected number of industrial and pharmaceutical processes. Despite the long term experience obtained with these processes, the pectinase according to the invention features a number of significant advantages over the enzymes currently used. Depending on the specific application, these advantages can include aspects like lower production costs, higher specificity towards the substrate, less antigenic, less undesirable side activities, higher yields when produced in a suitable microorganism, more suitable pH and temperature

ranges, better tastes of the final product as well as food grade and kosher aspects.

5 An important aspect of the pectinases according to the invention is that they cover a whole range of pH and temperature optima which are ideally suited for a variety of applications. For example many large scale processes benefit from relatively high processing temperatures of 50 degrees C or higher, e.g. to control the risks of microbial infections. Several pectinases according to the invention comply with this demand but at the same time they are not that heat stable that they resist attempts to inactivate the enzyme by an additional heat treatment. The latter feature allows production routes that yield final products free of residual enzyme activity. Similarly many feed and food products have slightly acidic pH values so that pectinases with acidic or near neutral pH optima are preferred for their processing. A PEC7 pectinase according to the invention complies with this requirement as well.

15 The polypeptides of the invention may also be added to animal feeds rich in pectin or xylogalacturonan, to reduce anti-nutritional effects of plant pectins and consequently improve production performances and welfare of the animals, as well reducing environmental pollution.

20 It has been shown that plant pectins increase digesta viscosity, fermentation and colonisation of bacterial proliferation in the gastro intestinal tract (Langhout, D.J. (1998). The role of the intestinal flora as affected by non-starch polysaccharides in broiler chicks. PhD thesis, Agricultural University Wageningen, The Netherlands). As a consequence, several digestive physiological parameters are altered (Johnson, I.T. and Gee, J.M. (1981). Effect of gel-forming gums on the intestinal unstirred layer and sugar transport in vitro. Gut 22:398-403. Johnson, I.T. and Gee, J.M. (1986). Gastrointestinal adaption in response to soluble non-available polysaccharides in the rat. British Journal of Nutrition 55:497-505, Johnson, I.T. , Gee, J.M. and Mahoney, R.R. (1984). Effect of dietary supplements of guar gum or cellulose on intestinal cell proliferation, enzyme levels and glucose transport in the rat. British Journal of Nutrition 52:477-487) resulting in reduced dietary nutrient, mineral and energy utilization (Langhout, D.J. and Schutte, J.B. (1996). Nutritional implications of pectins in chicks in relation to esterification and origin of pectins. Poultry Science 75:1236-1242, Smits, C.M.H., Veldman, A., Verkade, H.J. and Beynen, A.C. (1998). The inhibitory effect of carboxymethylcellulose with high viscosity on lipid absorption in broiler chickens coincides with reduced bile salt concentration and raised microbial numbers in the

35

small intestine. Poultry Science 77:1534-1539). The magnitude efficiency of dietary nutrient utilization is reduced, the effectivity in production performances (e.g. efficiency of producing milk, eggs, wool and meat) declines. Moreover, at reduced dietary nutrient utilization by the animal, excretion of and environmental pollution with e.g. nitrogenous compounds and heavy metals is increased.

Advantagous is that these fungal derived polypeptides of the invention have generally lower pH optima and their activities are therefore (more) capable of hydrolysis in such acidic environments as the stomach of an animal. With that, anti-nutritional properties of the plant cell wall fractions are already reduced early on in the digestive tract of the animal.

## **ABSTRACT**

The invention relates to newly identified polynucleotide sequences comprising genes that encode novel pectinases isolated from *Aspergillus niger*. The invention features the full length nucleotide sequence of the novel gene, the cDNA sequence comprising the full length coding sequence of the novel pectinase as well as the amino acid sequence of the full-length functional protein and functional equivalents thereof. The invention also relates to methods of using these enzymes in industrial processes and methods of diagnosing fungal infections. Also included in the invention are cells transformed with a polynucleotide according to the invention and cells wherein an pectinase according to the invention is genetically modified to enhance or reduce its activity and/or level of expression.

## CLAIMS

- 1) An isolated polynucleotide hybridisable to a polynucleotide according to SEQ ID NO:1 or SEQ ID NO: 2
- 2) An isolated polynucleotide according to claim 1 hybridisable under high stringency conditions to a polynucleotide according to SEQ ID NO:1 or SEQ ID NO: 2
- 3) An isolated polynucleotide according to claims 1 or 2 obtainable from a filamentous fungus.
- 4) An isolated polynucleotide according to claim 3 obtainable from *A. niger*.
- 5) An isolated polynucleotide encoding a polypeptide comprising an amino acid sequence according to SEQ ID NO: 3 or functional equivalents thereof.
- 6) An isolated polynucleotide encoding at least one functional domain of a polypeptide according to SEQ ID NO: 3 or functional equivalents thereof.
- 7) An isolated polynucleotide comprising a nucleotide sequence according to SEQ ID NO: 1 or SEQ ID NO: 2 or functional equivalents thereof
- 8) An isolated polynucleotide according to SEQ ID NO: 1 or SEQ ID NO: 2.
- 9) A vector comprising a polynucleotide sequence according to claims 1 to 8.
- 10) A vector according to claim 9 wherein said polynucleotide sequence according to claims 1 to 8 is operatively linked with regulatory sequences suitable for expression of said polynucleotide sequence in a suitable host cell.
- 11) A vector according to claim 10 wherein said suitable host cell is a filamentous fungus
- 12) A method for manufacturing a polynucleotide according to claims 1 – 8 or a vector according to claims 9 to 11 comprising the steps of culturing a host cell transformed with said polynucleotide or said vector and isolating said polynucleotide or said vector from said host cell.
- 13) An isolated polypeptide according to SEQ ID NO: 3 or functional equivalents thereof.
- 14) An isolated polypeptide according to claim 13 obtainable from *Aspergillus niger*
- 15) An isolated polypeptide obtainable by expressing a polynucleotide according to claims 1 to 8 or a vector according to claims 9 to 11 in an appropriate host cell, e.g. *Aspergillus niger*.
- 16) Recombinant pectinase comprising a functional domain of a PEC7 polypeptide.

- 17) A method for manufacturing a polypeptide according to claims 13 to 16 comprising the steps of transforming a suitable host cell with an isolated polynucleotide according to claims 1 to 8 or a vector according to claims 9 to 11, culturing said cell under conditions allowing expression of said polynucleotide and optionally purifying the encoded polypeptide from said cell or culture medium.
- 18) A recombinant host cell comprising a polynucleotide according to claims 1 to 8 or a vector according to claims 9 to 11.
- 19) A recombinant host cell expressing a polypeptide according to claims 13 to 16.
- 20) Purified antibodies reactive with a polypeptide according to claims 13 to 16.
- 21) Fusion protein comprising a polypeptide sequence according to claims 13 to 16.



# SEQUENCE LISTING

<110> DSM NV.

<120> Novel pectinase PEC7 and uses thereof

<130> 20765EP/P0

<160> 3

<170> XML to WIPO ST.25 Converter - <http://www.biomax.de/>

<210> 1

<211> 3826

<212> DNA

<213> *Aspergillus niger*

<400> 1

ggttgctggt	ttgtctgttc	cgcagactgc	agcaccatt	accacacaga	gcaatatcca	60
tctccatccg	acacacaggc	ccatataaac	atctcagctc	gagataatgt	tcccccggt	120
ttttgcccag	aaagcgaaga	ggggtcgcta	gcttcgagga	gttaatatcg	ctggccggct	180
cgtgcgggac	ggatcgattg	gcttgaggga	cactctgggg	taaattagtc	agggtcagtct	240
cggctgaatg	gcaggatgaa	tcaatcaa	ataagcgaac	aagcaagctt	tctcacacgt	300
tcaggggtgc	ggtgttggtt	ggctgcgcag	cagtaggcta	gtaggtatgc	cggcgtcatt	360
ggtggaattt	cctacagaga	gcccgtcgat	cgtgcatgaa	ggcgtcactc	aaacgccagt	420
gcatggagtc	ctccccgggt	tttctccgca	cagggaact	ggcgatatta	cttggatttg	480
tagttcggtg	gaagtagcac	cgaagtctgg	tctgaccgtc	tatcacctct	agtggaagcc	540
ccggtcagcg	ttcattaaag	gaactcaatg	ctcccaggca	cttacttcgc	gcatcaccgc	600
cattcacaat	gcaactaaga	gcttcggttt	tgtctctctt	cctggggctg	gcctccgttg	660
gccatgcagg	taatgtggaa	aacaaccaca	atgtctgcac	cgtccgagca	aacgggggac	720
accaagatga	cgtccccaat	attatggcgg	cgttcaaaga	gtgtggcaat	ggaggtacca	780
ttattttccc	cgaagaccaa	tcgtactgga	ttgcgacgag	actgcatccc	acattgaagg	840
acgtcgcaat	cgaatggcgg	gggaagtgga	cagtaagact	ccctcaatct	ccatctcgtg	900
acttgtgaaa	cgctgattcg	gtccagtttt	ccgacaacct	cacctactgg	cgtaacaact	960
cctaccccat	tgcgttccag	aacctatcat	ccggcttcat	tattagcggc	gacaacatca	1020
ccatcaatgg	ctatggcacc	ggcggcattg	atggcaatgg	caatacttgg	tacacagccg	1080
agaaggcgca	cagcgagccg	gggcgtccga	tgccatttgt	cttttggaac	gtgtctgagg	1140
ttattgttga	cagctttctac	gtcaaggatc	cgccctctg	gagtgtcaac	atcatgaacg	1200
ggactaacat	gcgtttcaac	aatatctact	gcaacgccac	ggctgtagat	gccccctggg	1260
gcgataactg	ggtgcagaat	acggatgggt	tcggtatgat	tctttttgtc	cgcgctctag	1320
tggaaatgggt	taggttctga	ctagcactcg	tatccagata	ccatggacgc	taccaacatc	1380
cagctcacca	acttcgtcta	ccaaggcgga	gatgactgca	tcgctatcaa	gccccgctcc	1440
tacaacatcg	acatccagaa	tgttacctgc	cgtggaggca	acggcattgc	cattggcagc	1500
ttgggtcaat	atttgggaaga	tagcagtgtt	gctaacattc	gcgtggacaa	ggtcaatgta	1560
cgtgatttgt	tcccgccac	catcgccatt	agtattaacc	gtaatccaga	tcatccgcta	1620
caacgaagac	atgcacaaca	gcgcctacct	caagacctgg	gtcggagctc	tcgtccccc	1680
aagtttcctac	gaaagcgccg	gcgtacctcg	tggcgatggc	tggggcagca	tccgtaacgt	1740
cctattttca	aacttcaatg	tacaaggcgc	aagcgctggc	ccttccatca	gtcaggacag	1800
tggagacaac	ggttcctatg	cgggtacaag	caagatgtct	atttcaa	ttgcgtttgt	1860
caatttcacg	ggatgggtgg	atactgagaa	gtctgtggtc	tcgacggtct	cctgctcaga	1920
ggtacatccg	tgctacaata	tcgactatga	caatgtggtg	ttgtatccag	ggaagaatgc	1980
cacaacagct	gggacagggt	cttgtaaata	tacagctgat	ggaggagtgc	atgggttgag	2040
tgggtgttga	tttgtggatc	gctaagggaag	cgatttgggt	gatatgtgta	tatatgactg	2100
caagtaagaa	ggatcaatgg	gtgacagtaa	tactctagaa	aaccgaggta	aatctcagca	2160
atatttcaga	accctagcat	agatagtcac	gacgtactgc	gtgaagaggg	acaacaagc	2220
agctagcaaa	gcaaaccccc	aaagcttgat	aacattcgca	aggcttgcac	tagcatctaa	2280

gttcagacac	aacctaatgc	aactttcctc	gcttggctgc	aatgtcaatc	atcgtcgtga	2340
catttgccctg	gattgatcaa	cggcggatcc	ctgtcaatca	ttccaatcct	tgggtcactc	2400
acggcacttg	ccgcaaggta	acgaaccaca	aggaaggtagg	ctctggtaga	tttcgacaga	2460
tgagttttcac	ccatggaaat	tccccatcct	tgacggtaggg	ttgttccgaa	ggaagtgtg	2520
ccattgagat	gacttcccaa	ccgtcctggt	ggactacact	ttgccaagat	gggatggagg	2580
ggtcattgta	cgaccttcat	ttaggcacat	gtctggccgt	gatgaataac	tcgcaagata	2640
ggacagggtga	agcacatctg	cctgggtgca	gtgacagttg	cgtacgtcac	tgggtaggac	2700
aggcctcatt	cccagccgat	tgaaggatgat	tcaatcgccg	ttcgggtttc	tgaacatgat	2760
gcctgcactg	tctcctttca	cactcggcat	cttccgagtg	actggggacc	cagaacggcg	2820
accttttcgg	gtataaatag	ctgcccactc	ctcctccttc	ttctttccact	tcctctcccc	2880
tttcagtgtg	ctatctccc	ctttagtagt	ttccacaatg	ccctttcatc	atatattttg	2940
agagttcatc	cctttttcta	tcatgggtgct	catcttttct	tctaataatat	atactcctac	3000
ttcttatata	tagaaatgca	tcgggtacat	cgaagtgcac	gctatgataa	ccatcgaccg	3060
tcttcatcaa	accctataat	gaatcacggg	tgggggaaca	cctttatcga	cgaggtcaat	3120
gatctctgtc	aagaaatcag	caatcggaag	aatgatgagt	ttcaatgcca	agagaaacac	3180
cgtggctaaa	gctgcccggc	tttgaatcac	tcatgacagt	tccgatgcat	gacaccaaag	3240
agccggcatg	catagccaaa	tcacttacca	gaacaatata	atctacttca	tgaatatgaa	3300
aaccttttgt	atatacgcaa	ttcaagaatt	gggcttttca	acgagggact	cagtggccgt	3360
cggagatata	aaaaatcatc	tcttgcaagt	caatgtaggt	tcataaccagc	ccacaaattg	3420
ctaatagcact	ggactctgac	cattgtttgc	actaggcatc	actcatgtca	gtacaatgtc	3480
ttaaaccaag	accttgtccc	aaggacttgc	cagttcattg	cattgttcaa	gatgccatgg	3540
cgcgatgaac	tcagatgcag	agctcgtcag	ttcttacgtc	cgatatctta	gctcgcagaa	3600
gcaatataact	acaacgcttg	gagcacacgc	accgaaatgc	cctaagcatc	tacacaacgc	3660
atgtgtatat	aaagatccta	agcagggctt	cagatgggtca	ggtgcatgca	catgcacgca	3720
ttcgagcatg	ctagagtagc	atcgacccca	ttgcgaccct	aaacaggggtc	ccagtaccag	3780
caaggcgcgg	acgaggaaag	cacttttcat	tgaagaaac	cgagca		3826

<210> 2

<211> 1272

<212> DNA

<213> *Aspergillus niger*

<220>

<221> CDS

<222> (1)..(1272)

<400> 2

atg	caa	cta	aga	gct	tcg	gtt	ttg	ctc	tct	ttc	ctg	ggg	ctg	gcc	tcc	48
Met	Gln	Leu	Arg	Ala	Ser	Val	Leu	Leu	Ser	Phe	Leu	Gly	Leu	Ala	Ser	
1			5						10					15		
gtt	ggc	cat	gca	ggt	aat	gtg	gaa	aac	cac	aat	gtc	tgc	acc	gtc		96
Val	Gly	His	Ala	Gly	Asn	Val	Glu	Asn	His	Asn	Val	Cys	Thr	Val		
			20					25					30			
cga	gca	aac	ggg	gga	cac	caa	gat	gac	gtc	ccc	aat	att	atg	gcg	gcg	144
Arg	Ala	Asn	Gly	Gly	His	Gln	Asp	Asp	Val	Pro	Asn	Ile	Met	Ala	Ala	
		35					40					45				
ttc	aaa	gag	tgt	ggc	aat	gga	ggt	acc	att	att	ttc	ccc	gaa	gac	caa	192
Phe	Lys	Glu	Cys	Gly	Asn	Gly	Gly	Thr	Ile	Ile	Phe	Pro	Glu	Asp	Gln	
	50				55					60						
tcg	tac	tgg	att	gcg	acg	aga	ctg	cat	ccc	aca	ttg	aag	gac	gtc	gca	240
Ser	Tyr	Trp	Ile	Ala	Thr	Arg	Leu	His	Pro	Thr	Leu	Lys	Asp	Val	Ala	
65					70					75				80		
atc	gaa	tgg	cgg	ggg	aag	tgg	aca	ttt	tcc	gac	aac	ctc	acc	tac	tgg	288
Ile	Glu	Trp	Arg	Gly	Lys	Trp	Thr	Phe	Ser	Asp	Asn	Leu	Thr	Tyr	Trp	
			85					90					95			
cgt	aac	aac	tcc	tac	ccc	att	gcg	ttc	cag	aac	cat	cat	gcc	ggc	ttc	336

Arg	Asn	Asn	Ser	Tyr	Pro	Ile	Ala	Phe	Gln	Asn	His	His	Ala	Gly	Phe		
		100						105					110				
att	att	agc	ggc	gac	aac	atc	acc	atc	aat	ggc	tat	ggc	acc	ggc	ggc	384	
Ile	Ile	Ser	Gly	Asp	Asn	Ile	Thr	Ile	Asn	Gly	Tyr	Gly	Thr	Gly	Gly		
		115					120					125					
att	gat	ggc	aat	ggc	aat	act	tgg	tac	aca	gcc	gag	aag	ggc	gac	acg	432	
Ile	Asp	Gly	Asn	Gly	Asn	Thr	Trp	Tyr	Thr	Ala	Glu	Lys	Gly	Asp	Thr		
	130					135					140						
cag	ccg	ggg	cgt	ccg	atg	cca	ttt	gtc	ttt	tgg	aac	gtg	tct	gag	gtt	480	
Gln	Pro	Gly	Arg	Pro	Met	Pro	Phe	Val	Phe	Trp	Asn	Val	Ser	Glu	Val		
145				150						155					160		
att	gtt	gac	agt	ttc	tac	gtc	aag	gat	ccg	ccc	ctc	tgg	agt	gtc	aac	528	
Ile	Val	Asp	Ser	Phe	Tyr	Val	Lys	Asp	Pro	Pro	Leu	Trp	Ser	Val	Asn		
				165				170						175			
atc	atg	aac	ggg	act	aac	atg	cgt	ttc	aac	aat	atc	tac	tgc	aac	gcc	576	
Ile	Met	Asn	Gly	Thr	Asn	Met	Arg	Phe	Asn	Asn	Ile	Tyr	Cys	Asn	Ala		
		180						185					190				
acg	gct	gta	gat	gcc	ccc	tgg	ggc	gat	aac	tgg	gtg	cag	aat	acg	gat	624	
Thr	Ala	Val	Asp	Ala	Pro	Trp	Gly	Asp	Asn	Trp	Val	Gln	Asn	Thr	Asp		
		195				200					205						
ggc	ttc	gat	acc	atg	gac	gct	acc	aac	atc	cag	ctc	acc	aac	ttc	gtc	672	
Gly	Phe	Asp	Thr	Met	Asp	Ala	Thr	Asn	Ile	Gln	Leu	Thr	Asn	Phe	Val		
	210					215					220						
tac	caa	ggc	gga	gat	gac	tgc	atc	gct	atc	aag	ccc	cgc	tcc	tac	aac	720	
Tyr	Gln	Gly	Gly	Asp	Asp	Cys	Ile	Ala	Ile	Lys	Pro	Arg	Ser	Tyr	Asn		
225				230						235					240		
atc	gac	atc	cag	aat	gtt	acc	tgc	cgt	gga	ggc	aac	ggc	att	gcc	att	768	
Ile	Asp	Ile	Gln	Asn	Val	Thr	Cys	Arg	Gly	Gly	Asn	Gly	Ile	Ala	Ile		
				245				250						255			
ggc	agc	ttg	ggc	caa	tat	ttg	gaa	gat	agc	agt	gtt	gct	aac	att	cgc	816	
Gly	Ser	Leu	Gly	Gln	Tyr	Leu	Glu	Asp	Ser	Ser	Val	Ala	Asn	Ile	Arg		
		260					265					270					
gtg	gac	aag	gtc	aat	atc	atc	cgc	tac	aac	gaa	gac	atg	cac	aac	agc	864	
Val	Asp	Lys	Val	Asn	Ile	Ile	Arg	Tyr	Asn	Glu	Asp	Met	His	Asn	Ser		
		275					280					285					
gcc	tac	ctc	aag	acc	tgg	gtc	gga	gct	ctc	gtc	ccc	caa	agt	tcc	tac	912	
Ala	Tyr	Leu	Lys	Thr	Trp	Val	Gly	Ala	Leu	Val	Pro	Gln	Ser	Ser	Tyr		
	290					295					300						
gaa	agc	gcc	ggc	gta	cct	cgt	ggc	gat	ggc	tgg	ggc	agc	atc	cgt	aac	960	
Glu	Ser	Ala	Gly	Val	Pro	Arg	Gly	Asp	Gly	Trp	Gly	Ser	Ile	Arg	Asn		
305				310						315					320		
gtc	cta	ttt	tca	aac	ttc	aat	gta	caa	ggc	gca	agc	gct	ggc	cct	tcc	1008	
Val	Leu	Phe	Ser	Asn	Phe	Asn	Val	Gln	Gly	Ala	Ser	Ala	Gly	Pro	Ser		
				325					330					335			
atc	agt	cag	gac	agt	gga	gac	aac	ggt	tcc	tat	gcg	ggt	aca	agc	aag	1056	
Ile	Ser	Gln	Asp	Ser	Gly	Asp	Asn	Gly	Ser	Tyr	Ala	Gly	Thr	Ser	Lys		
			340					345					350				
atg	tct	att	tca	aat	gtt	gcg	ttt	gtc	aat	ttc	acg	gga	tgg	gtg	gat	1104	
Met	Ser	Ile	Ser	Asn	Val	Ala	Phe	Val	Asn	Phe	Thr	Gly	Trp	Val	Asp		
		355					360					365					
act	gag	aag	tct	gtg	gtc	tgc	acg	gtc	tcc	tgc	tca	gag	gta	cat	ccg	1152	
Thr	Glu	Lys	Ser	Val	Val	Ser	Thr	Val	Ser	Cys	Ser	Glu	Val	His	Pro		
	370					375					380						
tgc	tac	aat	atc	gac	tat	gac	aat	gtg	gtg	ttg	tat	cca	ggg	aag	aat	1200	
Cys	Tyr	Asn	Ile	Asp	Tyr	Asp	Asn	Val	Val	Leu	Tyr	Pro	Gly	Lys	Asn		
385					390					395					400		
gcc	aca	aca	gct	ggg	aca	ggg	tct	tgt	aaa	tat	aca	gct	gat	gga	gga	1248	

Ala Thr Thr Ala Gly Thr Gly Ser Cys Lys Tyr Thr Ala Asp Gly Gly  
 405 410 415  
 gtg cat ggg ttg agt ggg tgt tga  
 Val His Gly Leu Ser Gly Cys  
 420

1272

<210> 3  
 <211> 423  
 <212> PRT  
 <213> Aspergillus niger

<400> 3  
 Met Gln Leu Arg Ala Ser Val Leu Leu Ser Phe Leu Gly Leu Ala Ser  
 1 5 10 15  
 Val Gly His Ala Gly Asn Val Glu Asn His Asn Val Cys Thr Val  
 20 25 30  
 Arg Ala Asn Gly Gly His Gln Asp Asp Val Pro Asn Ile Met Ala Ala  
 35 40 45  
 Phe Lys Glu Cys Gly Asn Gly Gly Thr Ile Ile Phe Pro Glu Asp Gln  
 50 55 60  
 Ser Tyr Trp Ile Ala Thr Arg Leu His Pro Thr Leu Lys Asp Val Ala  
 65 70 75 80  
 Ile Glu Trp Arg Gly Lys Trp Thr Phe Ser Asp Asn Leu Thr Tyr Trp  
 85 90 95  
 Arg Asn Asn Ser Tyr Pro Ile Ala Phe Gln Asn His His Ala Gly Phe  
 100 105 110  
 Ile Ile Ser Gly Asp Asn Ile Thr Ile Asn Gly Tyr Gly Thr Gly Gly  
 115 120 125  
 Ile Asp Gly Asn Gly Asn Thr Trp Tyr Thr Ala Glu Lys Gly Asp Thr  
 130 135 140  
 Gln Pro Gly Arg Pro Met Pro Phe Val Phe Trp Asn Val Ser Glu Val  
 145 150 155 160  
 Ile Val Asp Ser Phe Tyr Val Lys Asp Pro Pro Leu Trp Ser Val Asn  
 165 170 175  
 Ile Met Asn Gly Thr Asn Met Arg Phe Asn Asn Ile Tyr Cys Asn Ala  
 180 185 190  
 Thr Ala Val Asp Ala Pro Trp Gly Asp Asn Trp Val Gln Asn Thr Asp  
 195 200 205  
 Gly Phe Asp Thr Met Asp Ala Thr Asn Ile Gln Leu Thr Asn Phe Val  
 210 215 220  
 Tyr Gln Gly Gly Asp Asp Cys Ile Ala Ile Lys Pro Arg Ser Tyr Asn  
 225 230 235 240  
 Ile Asp Ile Gln Asn Val Thr Cys Arg Gly Gly Asn Gly Ile Ala Ile  
 245 250 255  
 Gly Ser Leu Gly Gln Tyr Leu Glu Asp Ser Ser Val Ala Asn Ile Arg  
 260 265 270  
 Val Asp Lys Val Asn Ile Ile Arg Tyr Asn Glu Asp Met His Asn Ser  
 275 280 285  
 Ala Tyr Leu Lys Thr Trp Val Gly Ala Leu Val Pro Gln Ser Ser Tyr  
 290 295 300  
 Glu Ser Ala Gly Val Pro Arg Gly Asp Gly Trp Gly Ser Ile Arg Asn  
 305 310 315 320  
 Val Leu Phe Ser Asn Phe Asn Val Gln Gly Ala Ser Ala Gly Pro Ser  
 325 330 335  
 Ile Ser Gln Asp Ser Gly Asp Asn Gly Ser Tyr Ala Gly Thr Ser Lys  
 340 345 350

[illegible]

**PCT/EP2003/005726**



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**